Skip to main contentAI and Advanced
/
JAGSNPHARM · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
JA
NSE · Equity shares · Major Drugs2.45 · 1.08%
Jagsonpal Pharmaceuticals JAGSNPHARM
NSE:INR 228.28
BSE:INR 229.5
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for JAGSNPHARM
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 225.83
Day rangeINR 217.81 — INR 230.95
52-week rangeINR 154.9 — INR 301.8
Volume56,444
Market cap1,459.66
P/E28.75
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)287.23
Net Income (INR Cr)43.08
Rev Growth (5 Year %)8.85
EPS Growth (5 Year %)19.36
P/E Ratio28.75
Book Value29.6
EPS6.54
Price/BV7.71Computed
Research path: Interpret Jagsonpal Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
JAGSNPHARMJagsonpal Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 316.68 | 278.26 | 217.08 |
| Other Liabilities Total | 1.18 | 1.7 | 0.92 |
| Common Stock Total | 13.39 | 13.28 | 13.22 |
| Other Current Assets Total | 5.07 | 0.07 | 17.29 |
| Total Assets | 316.68 | 278.26 | 217.08 |
| Current Portof LT Debt/Capital Leases | 1.58 | 1.61 | 1.38 |
| Cash | 10.04 | 11.22 | 12.76 |
| Total Equity | 276.17 | 239.95 | 187.4 |
| Long Term Investments | 85.11 | 17.39 | 5.17 |
| Retained Earnings(Accumulated Deficit) | 262.78 | 212.22 | 163.06 |
| Total Common Shares Outstanding | 6.7 | 6.64 | 6.61 |
| Tangible Book Valueper Share Common Eq | 29.6 | 23.24 | 28.35 |
| Goodwill Net | 9.69 | 9.69 | Not available |
| Total Liabilities | 40.51 | 38.31 | 29.68 |
| Total Debt | 8.17 | 9.24 | 8.94 |
| Short Term Investments | 96.14 | 117.52 | 135.17 |
| Cashand Short Term Investments | 106.18 | 128.73 | 147.93 |
| Total Receivables Net | 17.19 | 14.3 | 15.68 |
| Deferred Income Tax | 4.44 | 3.07 | 2.07 |
| Accounts Receivable-Trade Net | 17.19 | 13.18 | 10.95 |
| Property/Plant/Equipment Total-Net | 7.35 | 8.84 | 9.3 |
| Total Current Liabilities | 28.3 | 25.9 | 19.13 |
| Total Inventory | 14.64 | 16.43 | 16.99 |
| Accounts Payable | 11.58 | 9.73 | 7.6 |
| Other Currentliabilities Total | 15.14 | 13.55 | 9.4 |
| Total Long Term Debt | 6.59 | 7.63 | 7.56 |
| Intangibles Net | 68.27 | 75.92 | Not available |
| Other Long Term Assets Total | 3.1 | 4.42 | 2.11 |
| Note Receivable-Long Term | 0.07 | 0.8 | 1.25 |
| Total Current Assets | 143.09 | 161.19 | 199.25 |
| Capital Lease Obligations | 6.59 | 7.63 | 7.56 |
| Accumulated Depreciation Total | Not available | -0.87 | -1.13 |
| Accrued Expenses | Not available | 1.01 | 0.75 |
| Other Equity Total | Not available | 0.4 | 0 |
| Prepaid Expenses | Not available | 1.66 | 1.36 |
| Additional Paid-In Capital | Not available | 14.06 | 11.12 |
| Property/Plant/Equipment Total-Gross | Not available | 9.7 | 10.43 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.25
Price to Sale Ratio5.08
Growth
Debt 5Yr CAGR %3.76
Margins
Operating Margin 12m16.21
Operating Margin 5y Avg15.2
Net Profit Margin 12m15
Net Profit Margin 5y13.66
Yield
Dividend Yield %1.8
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk33.6
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Aurobindo Pharma | INR 1,536 | 88,543.41 | 25.52 | — |
| Neuland Laboratories | INR 18,400 | 23,672.85 | 66.08 | — |
| Pfizer | INR 4,597.95 | 20,988.72 | 27.6 | — |
| Unichem Laboratories | INR 543.7 | 3,827.96 | 54.87 | — |
| Themis Medicare | INR 110.2 | 1,015.38 | 651.23 | — |
Shareholding
Ownership
- Promoter
- 69.05%
- FII
- 2.30%
- MF
- 0.11%
- Other
- 28.65%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Jagsonpal Pharma Completes Aequitas Healthcare Acquisition; Boosts Inorganic Growth - WhalesbookMarket news · 17 Jul 2026, 4:56 pm
Jagsonpal Pharma Completes Aequitas Healthcare Acquisition; Boosts Inorganic Growth Whalesbook
Jagsonpal Pharmaceuticals completes 69.77% stake acquisition in Aequitas Healthcare - Business UpturnMarket news · 7 Jul 2026, 1:40 pm
Jagsonpal Pharmaceuticals completes 69.77% stake acquisition in Aequitas Healthcare Business Upturn
Jagsonpal Pharmaceuticals Downgraded to Sell Amid Mixed Financial and Technical Signals - MarketsMojoMarket news · 7 Jul 2026, 9:38 am
Jagsonpal Pharmaceuticals Downgraded to Sell Amid Mixed Financial and Technical Signals MarketsMojo
Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals - MarketsMojoMarket news · 7 Jul 2026, 8:00 am
Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals MarketsMojo
Jagsonpal Pharmaceuticals Ltd is Rated Strong Sell - MarketsMojoMarket news · 7 Jul 2026, 2:09 am
Jagsonpal Pharmaceuticals Ltd is Rated Strong Sell MarketsMojo
Jagsonpal Pharmaceuticals Upgraded to Sell on Technical Improvements Despite Financial Challenges - MarketsMojoMarket news · 7 Jul 2026, 1:46 am
Jagsonpal Pharmaceuticals Upgraded to Sell on Technical Improvements Despite Financial Challenges MarketsMojo
Corporate actions
Events
- annual General MeetingBuy Back of Shares
- dividendRs.4.0000 per share(200%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsBuy Back of Shares
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Jagsonpal Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.
Company facts
- Industry
- Major Drugs
- Sector
- Major Drugs
- NSE Code
- JAGSNPHARM
- BSE Code
- 507789
Questions
Stock FAQ
What is the symbol and ISIN of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals has the symbol JAGSNPHARM and ISIN - INE048B01035.
What is the current price of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals is currently trading at INR 228.28.
What are the year high and year low of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals has a year high of INR 301.80 and a year low of INR 154.90.
What is the market capitalization of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals has a market capitalization of INR 1,459.66 crore.
What is the P/E ratio of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals has a P/E ratio of 28.75.
What is the dividend yield of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals has a dividend yield of 1.80%.
How is the financial performance of Jagsonpal Pharmaceuticals based on revenue, net income, and EPS?
Jagsonpal Pharmaceuticals has revenue of INR 287.23 crore, net income of INR 43.08 crore, and EPS of INR 6.55.
What is the book value of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals has a book value of INR 29.60.
What is the debt-to-equity ratio of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Jagsonpal Pharmaceuticals?
Jagsonpal Pharmaceuticals has a price-to-book ratio of 7.71 and a price-to-sales ratio of 5.08.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.